AIM Rule 17 and Schedule 2(g) Update

hVIVO plc

("hVIVO", the "Company" or the "Group")

AIM Rule 17 and Schedule 2(g) Update

hVIVO plc (AIM: HVO), a fast-growing early-stage Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces the following update in relation to directors' disclosure for Martin Gouldstone, Non-Executive Director of the Company, pursuant to AIM Rule 17 and Schedule 2(g) of the AIM Rules for Companies.

Oncimmune Holdings plc, a company of which Martin Gouldstone is CEO, was placed into administration on 26 March 2025.

For further information please contact:

Notes to Editors

hVIVO plc (Ticker: HVO) is a rapidly growing early-stage Contract Research Organisation (CRO) and the global leader in human challenge trials. The company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world's ten largest biopharma companies.

hVIVO specialises in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its state-of-the-art quarantine facility in London-the largest of its kind worldwide. The company also offers comprehensive virology and immunology laboratory services under the hLAB brand.

Through its German subsidiary, CRS, hVIVO operates a 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. Its second subsidiary, Venn Life Sciences, offers Early Drug Development Consulting and Biometry services to the biopharma sector.

The Group provides fully integrated drug development solutions from preclinical stages through Phase II trials, alongside patient recruitment via FluCamp. Additionally, its five clinical sites support outpatient Phase II and III trials, ensuring a seamless and efficient pathway from discovery to late-stage development.